RANI

Rani Therapeutics Holdings Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 6/10
  • Value↑ 5/10
Rani Therapeutics Holdings sales and earnings growth
RANI Growth
Good
  • Revenue Y/Y↑ 22.72%
  • EPS Y/Y↑ 70.71%
  • FCF Y/Y↑ 50.46%
Rani Therapeutics Holdings gross and profit margin trends
RANI Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -929.10%
  • ROIC 5Y↓ -69.25%
Rani Therapeutics Holdings net debt vs free cash flow
RANI Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -13.4

Rani Therapeutics Holdings stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks